Print

Shionogi, Inc.-ViiV Healthcare to File HIV Drug dolutegravir for Approval  
10/4/2012 7:27:29 AM

GlaxoSmithKline PLC (GSK.LN), a pharmaceutical company, said Thursday that Shionogi-ViiV Healthcare LLC has completed the initial clinical registration package for dolutegravir in HIV. MAIN FACTS: -Shionogi-ViiV Healthcare LLC, a joint venture between ViiV Healthcare Ltd (a global specialist HIV company established by GlaxoSmithKline and Pfizer, Inc.) and Shionogi & Co., Ltd, said that the phase III data required for initial regulatory filings of the investigational integrase inhibitor dolutegravir in adults infected with HIV are in house.
//-->